# Sattva S. Neelapu

Source: https://onco.cc/people/sattva-neelapu/  
OnCo record `sattva-neelapu` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led ZUMA-1, the trial that made axicabtagene ciloleucel the first CAR-T therapy approved for lymphoma.

## Summary

Sattva Neelapu was principal investigator of ZUMA-1, which showed axicabtagene ciloleucel produces durable remissions in about 40% of patients with refractory large B-cell lymphoma and led to the first CAR-T approval in lymphoma, and co-led ZUMA-5 in follicular lymphoma. He co-authored the CARTOX consensus on managing cytokine release syndrome and neurotoxicity and studies mechanisms of CAR-T resistance.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: lymphoma; car-t; cell-therapy
- Role: Professor and Deputy Chair, Department of Lymphoma and Myeloma, MD Anderson Cancer Center
- Specialisms: CAR T-cell therapy; Lymphoma; CAR-T toxicity management; Resistance mechanisms

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Neelapu%20SS%5BAuthor%5D%20axicabtagene

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [CD19](https://onco.cc/targets/cd19/)
- drugs: [Axicabtagene ciloleucel](https://onco.cc/drugs/axicabtagene-ciloleucel/)
- institutions: [MD Anderson Cancer Center](https://onco.cc/institutions/md-anderson/)
- trials: [ZUMA-1](https://onco.cc/trials/zuma-1/), [ZUMA-7](https://onco.cc/trials/zuma-7/)
- key papers: [ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma](https://onco.cc/key-papers/paper-zuma-1-axi-cel-nejm-2017/)
- journals: [Nature Reviews Clinical Oncology](https://onco.cc/journals/nature-reviews-clinical-oncology/)

---
JSON: https://onco.cc/api/v1/entities/sattva-neelapu.json